PRINCETON, N.J., Jan. 25 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Steven Leventer, Ph.D. has been appointed Vice President, Clinical Research Neuroscience.
"We are very pleased to have Steve join PharmaNet Development Group," commented Dalvir Gill, Chief Operating Officer, Late Stage Development. "Steve is a recognized expert in the fields of clinical trial design and clinical development planning. His combination of neuroscience expertise and dedication to efficiency and quality provides the right complement to our existing organization."
Dr. Leventer has over twenty years of experience in all phases of drug development. He has spent most of his career leading clinical teams at large global pharmaceutical and contract research organizations in the development of therapeutics for Alzheimer's disease, schizophrenia, depression and other central nervous system diseases. He was trained as a neurochemist and has had post-doctoral fellowships and faculty appointments at the University of Texas, Western Psychiatric Institute and Clinic, and Loyola University Stritch School of Medicine.
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and more than 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.
Contact: Anne-Marie Hess Phone: (609) 951-6842 Email: firstname.lastname@example.org
SOURCE PharmaNet Development Group, Inc.
|SOURCE PharmaNet Development Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved